

CORPORATE FACT SHEET

Winter 2006

AMO at a Glance

- Focused ophthalmic medical device company with leading positions in growing markets
- Publicly traded on NYSE under "EYE" ticker symbol
- 2004 sales of \$742.1 million
- Headquartered in Santa Ana, California
- Approximately 3,500 employees worldwide
- Operations in 24 countries; presence in more than 60 countries
- Manufacturing facilities on three continents

Management

Jim Mazzo

President & CEO

Randy Meier

Executive VP & CFO

Aimee Weisner

Corporate VP, General Counsel

Jane Rady

Corporate VP, Strategy & Technology

Peter Nolan

Sr. VP, WWOPs

Francine Meza

Sr. VP, Human Resources

Sheree Aronson

VP, Corporate Communications & IR

Russ Trenary

Corporate VP & CMO

Holger Heidrich

President, Cataract/Implant Group

Jim Cooke

President, Eye Care Group

Doug Post

President, Laser Vision Correction Group

Board of Directors

William R. Grant

Galen Associates

Christopher G. Chavez

Advanced Neormodulation Systems

William J. Link

Versant Ventures

James V. Mazzo

Advanced Medical Optics

Michael A. Mussallem

Edwards Lifesciences

Deborah J. Neff

Predicant Biosciences, Inc.

James O. Rollans

Retired (Formerly Fluor)

Elizabeth H. Dávila

Formerly VISX, Inc.


Advanced Medical Optics Corporate Profile

Advanced Medical Optics, Inc. (AMO) is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. AMO became an independent, publicly traded company in June 2002, following a successful spin-off from Allergan, Inc. The company is based in Santa Ana, California and employs approximately 3,500 people worldwide. AMO has operations in 24 countries, with a presence in more than 60 countries.

Where We Compete

AMO's cataract, refractive and eye care businesses compete in large, demographically driven markets. We hold leading global positions in most major product categories. Our differentiated surgical product offering is among the industry's most comprehensive and includes primarily intraocular lenses (IOL), laser vision correction systems, phacoemulsification systems, viscoelastics and microkeratomes. Our eye care product line includes primarily multipurpose and hydrogen peroxide solutions.

\$4.1 Billion Global Market



Sources: Market Scope 2004; HPR; IRI; AC Nielsen; IMS; industry analysts reports

How Our Products Are Used

Cataract surgery is performed to restore clear vision when the eye's natural lens becomes hard and opaque. Using phacoemulsification, a surgeon inserts an ultrasound needle through a small incision in the cornea to soften and break up the lens into fragments, which are aspirated from the capsular bag. A flexible, folded IOL is inserted through the incision into the lens capsule. During the procedure, viscoelastic – a gelatinous substance – is injected into the eye to protect ocular surfaces and provide the surgeon room to operate. AMO's flagship cataract surgical device brands include the Sovereign® phacoemulsification system with WhiteStar® technology, Healon® and Vitrac® viscoelastics and a portfolio of IOLs such as Tecnis® and Sensor®.



Refractive surgery is performed to address abnormal eye conditions whereby an image does not focus properly on the retina. The predominant procedure is LASIK, in which a microkeratome creates a corneal flap and an excimer laser reshapes the cornea. IOLs are being used increasingly to address refractive disorders. They include traditional IOLs, where the natural lens is removed, and phakic IOLs, where the natural lens remains in place. AMO's primary refractive products include the STAR S4 IR™ Laser System, WaveScan Wavefront® system, CustomVue™ procedure, Amadeus™ II microkeratome, Verisyse™ phakic IOL, and ReZoom™ and Tecnis® multifocal IOLs.

Eye care products are used to clean, disinfect and lubricate contact lenses and make them safe and comfortable. AMO's leading eye care brands include COMPLETE® MoisturePlus™ multipurpose solution, blink™ and Blink-n-Clean® rewetters, and UltraCare® and Ultrazyme® hydrogen peroxide systems. AMO recently launched its first-ever contact lens product in Europe and Asia Pacific under the COMPLETE® Aquavision™ brand.



Glaucoma implants are used in patients with medically uncontrollable glaucoma and poor surgical prognosis to help reduce ocular pressure and drain fluid. AMO manufactures and markets the Baerveldt® implant.

AMO
ADVANCED MEDICAL OPTICS
Innovating Vision

AMO Milestones

Jul 2002: Completed spin-off from Allergan

Aug 2002: Reprioritized R&D pipeline

Jun 2003: Increased financial flexibility through recapitalization

Aug 2003: Launched COMPLETE® MoisturePlus™, first contact lens solution to relieve dryness and discomfort

Nov 2003: Purchased Eye Care manufacturing facility in Spain

Apr 2004: Launched StabilEyes™ capsular tension ring

Jun 2004: Acquired Pfizer ophthalmic surgical business for \$450 million; completed related recapitalization

Jul 2004: Launched COMPLETE® Aquavision™ contact lenses (Europe and Asia Pacific)

Oct 2004: Launched Verisyse™ phakic IOL, first FDA-approved technology of its kind to be sold in U.S.

Mar 2005: Gained FDA approval on ReZoom™ multifocal IOL for cataract patients

May 2005: Acquired Quest Vision for novel accommodating IOL technologies

May 2005: Acquired VISX Incorporated in \$1.3 billion transaction

Recent News

AMO Completes Acquisition of VISX, Inc. (5/31/05)

AMO Acquires Quest Vision for Development of Accommodating IOL Designs (5/4/05)

ReZoom™ Multifocal IOL Receives FDA Approval (3/28/05)

FDA Approves Tecnis® Foldable Acrylic Lens for Cataract Patients (8/10/05)

FDA Approves STAR S4 IR™ Laser System for Treatment of High Myopia with Astigmatism (9/7/05)

Headquarters

1700 E. St. Andrew Place
Santa Ana, CA 92705
(714) 247-8200
www.amo-inc.com

Contacts

Media: Steve Chesterman,
714-247-8711
steve.chesterman@amo-inc.com

Investors: Erika Richmond,
714-247-8348
erika.richmond@amo-inc.com


Technological Leadership

AMO is dedicated to advancing the science of vision through continuous development of superior technologies that enhance patient outcomes and improve practitioner productivity. To that end, we strive to constantly access the best ideas through an operating structure whereby Corporate Development and Research & Development are managed together under a single corporate function called Strategy & Technology.

This unique approach promotes a technological open-mindedness that ensures proper prioritization of our internal R&D resources in concert with the pursuit of progressive innovations from outside the company. Our R&D teams represent a full breadth of ophthalmic surgical technology skill and expertise, deep knowledge of biomaterials and proficiency in eye care formulation chemistry. We believe our success depends on our ability to foster a stimulating environment that continues to attract the highest-caliber scientists and engineers who share our passion for creating technologies that ease human suffering. AMO's commitment to continuous innovation is evident in our increased investment in R&D. Percentages in the adjacent chart represent R&D spend as a percent of sales.

* Excludes \$28.1 million in charges for in-process research and development; includes AMO and VISX R&D expenses.

R&D Spending



AMO Technology Firsts

- Foldable IOL in U.S.
- Multifocal IOL in U.S.
- Phakic IOL in U.S.
- Aspheric IOL with FDA claim for improved functional vision
- Occlusion mode
- WhiteStar® technology
- Advanced fluidics
- Peroxide disinfection system
- MPS addressing comfort and dryness
- Three-coordinate eye tracking (VISX)
- Iris registration (VISX)
- Fourier calculation of wavefront data (VISX)
- Broadest range for custom LASIK, most recently for mixed astigmatism (VISX)

Vision Facts

- About 60% of those over 60 years old have cataracts. (Source: Eye Surgery Education Council)
- Cataracts are a leading cause of vision loss among adults 55 and older. (Source: Eye Care America)
- Approximately 52% of people has some form of myopia or hyperopia. (Source: American Academy of Ophthalmology)
- Over 30 million Americans wear contact lenses. (Source: American Optometric Association).
- LASIK surgery accounts for more than 90 percent of all refractive surgical procedures in the U.S. (Source: MarketScope)
- LASIK is performed by approximately 3,600 U.S. surgeons (Source: MarketScope)